277 related articles for article (PubMed ID: 19289419)
1. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M; Ferdani R; Shokeen M; Anderson CJ
Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
9. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
10. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
11. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
[TBL] [Abstract][Full Text] [Related]
13. A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu.
Locke LW; Chordia MD; Zhang Y; Kundu B; Kennedy D; Landseadel J; Xiao L; Fairchild KD; Berr SS; Linden J; Pan D
J Nucl Med; 2009 May; 50(5):790-7. PubMed ID: 19372473
[TBL] [Abstract][Full Text] [Related]
14. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.
Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999
[TBL] [Abstract][Full Text] [Related]
15. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
16. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.
Wei L; Butcher C; Miao Y; Gallazzi F; Quinn TP; Welch MJ; Lewis JS
J Nucl Med; 2007 Jan; 48(1):64-72. PubMed ID: 17204700
[TBL] [Abstract][Full Text] [Related]
18. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]